|
Avacta Group PLC on Monday said its lead programme faridoxorubicin showed favourable safety and tolerability in patients with salivary gland cancers. The Wetherby, West Yorkshire-based life sciences company said faridoxorubicin showed positive tolerability and safety in patents across both the every three weeks and every two weeks dosing regiments. ‘The trial data also demonstrate a robust reduction in toxicities associated with conventional doxorubicin therapy, with preliminary efficacy in patients with salivary gland cancers and soft tissue sarcomas,’ Avacta added. Faridoxorubicin is a form of doxorubicin designed to reduce the systemic side effects of conventional chemotherapy and concentrate the active payload in the tumour microenvironment. Doxorubicin is a chemotherapy drug used to treat cancer. Separately, Avacta says it raised about £16 million gross from institutional and ‘high net worth’ investors via an oversubscribed placing of 25.4 million new shares at 63 pence per share. Avacta will use the net proceeds of the placing as additional working capital to progress its research & development programmes into the second half of 2026, including progressing the faridoxorubicin phase 1b trial and planned initiation of the FAP-EXd phase Ia trial. Avacta shares fell 5.6% to 65.11 pence each on Monday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
